From frontline disruption to bispecific architectures and a new generation of payloads, Chicago is set to host the most consequential antibody–drug conjugate readouts of the cycle.
The antibody–drug conjugate (ADC) field arrives at ASCO 2026 in a different shape than it left San Diego a year ago. What was once a category dominated by a handful of validated targets has become a multi-mechanistic ecosystem — where payload chemistry, bispecific engineering and combination strategy are increasingly the basis of competitive differentiation.
This pre-conference briefing distills the readouts, assets and strategic narratives most likely to move the oncology market in the months ahead.
Five Catalysts Reshaping the ADC Conversation
Frontline Disruption in Lung Cancer
Sac-TMT + PembrolizumabKelun-Biotech and Merck & Co. are positioning a TROP2-directed ADC plus checkpoint inhibitor as a potential 1L challenger in PD-L1+ advanced NSCLC, with Phase 3 OptiTROP-Lung05 data on deck.
- Possible practice-changing signal
- First Phase 3 ADC + IO combo to read out in 1L NSCLC
- Could mark a structural shift in frontline sequencing
The Rise of Bispecific ADCs
JSKN016 · TROP2 / HER3Alphamab Oncology brings a first-in-class anti-TROP2/HER3 bispecific ADC into Phase 1 readouts in HER2-negative locally advanced or metastatic breast cancer — a signal that dual-targeting architectures are leaving theory and entering the clinic.
- Next-generation dual-targeting design
- Engineered for improved tumor selectivity
- Potential answer to adaptive resistance
Nectin-4 Beyond Urothelial
CRB-701 (SYS6002)Corbus Pharmaceuticals’ next-generation Nectin-4 ADC is being evaluated in recurrent or metastatic cervical cancer — a Phase 1/2 readout that could meaningfully expand the addressable footprint of the target class.
- Extends Nectin-4 reach beyond urothelial cancer
- Opens a pan-squamous opportunity
- Engineered for improved ADC stability
Conjugation Chemistry, Validated
TUB-040 · NaPi2b ADCTubulis presents NAPISTAR 1-01 Phase 1 dose-escalation monotherapy data for a novel NaPi2b-targeting exatecan ADC in platinum-resistant ovarian cancer — a critical platform-validation moment for proprietary linker chemistry.
- Showcases the proprietary P5 conjugation platform
- Focused on systemic tolerability optimization
- Highly stable payload delivery profile
Payload Innovation Goes Synthetic
AKTX-101 · TROP2 RNA-splicingAkari Therapeutics moves the conversation past topoisomerase and MMAE with a TROP2 ADC carrying an RNA-splicing modulator payload, explored in synergy with a K-Ras inhibitor in KRAS-mutated pancreatic cancer.
- Genuinely novel RNA-splicing payload class
- Differentiation beyond Topo-I and MMAE ecosystems
- Probing ADC + targeted-therapy combinations
The Target Map at ASCO 2026
TROP2 has emerged as one of the most contested target spaces of the meeting, while HER2 lifecycle expansion continues to push beyond traditional breast cancer positioning. HER2-low and biomarker-stratified subsets remain major battlegrounds.
Phase 3 & Market-Shaping Programs
Enfortumab Vedotin + Pembrolizumab
3.5-year follow-up from EV-302 is expected to reinforce durability leadership in 1L metastatic urothelial cancer and define the long-term survival benchmark for next-generation challengers.
Datopotamab Deruxtecan (Dato-DXd)
Competitive pressure intensifies in TROP2-directed breast cancer as Dato-DXd’s positioning is benchmarked directly against entrenched standards.
Trastuzumab Deruxtecan (Enhertu / T-DXd)
Continues to expand treatment duration and frontline dominance — the flagship ADC by which the rest of the field is measured.
Sacituzumab Govitecan
Comparative payload differentiation against DXd-based contenders becomes a defining narrative as the TROP2 battlefield grows more crowded.
Sacituzumab Tirumotecan (Sac-TMT)
A China-origin ADC making a credible challenge to TROP2 dominance in NSCLC and signaling a globalizing innovation curve.
Telisotuzumab Vedotin
Combination strategies and biomarker-driven selection are increasingly defining competitive advantage in the lung cancer ADC pathway.
Next-Generation Platform Innovation Zone
A defining shift at ASCO 2026: ADC engineering competition is moving away from single-asset positioning and toward platform ecosystems. Expect multiple sponsors to use this meeting to disclose architecture-level differentiation, not just clinical readouts.
BNT326
Future ADC architectures with differentiated topo-I payload systems for HER3-driven solid tumors.
SKB500
Platform-level diversification — specific targets undisclosed, but the architecture itself is the message.
BNT324
Pivotal-design topo-I ADC entering advanced prostate cancer where the IO + ADC convergence narrative is gaining real traction.
BNT323
Pushing HER2 topo-I ADC reach into a broader range of gynecologic malignancies.
The Competitive Intelligence Table
A consolidated view of the assets, sponsors, modalities and strategic implications most worth tracking across the meeting.
| ADC Asset | Company | Phase | Target | Payload / Platform | Tumor Type | Format | Abstract | Strategic Read |
|---|---|---|---|---|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Pfizer / Astellas | Phase 3 | Nectin-4 | MMAE vedotin platform | 1L mUC | Oral | 4507 | Defines the long-term survival benchmark for next-gen challengers in 1L mUC. |
| Datopotamab Deruxtecan | AstraZeneca / Daiichi Sankyo | Phase 3 | TROP2 | DXd topoisomerase I | mTNBC | Oral | 1002 | Pivotal readout positioning DXd against SG in TROP2-driven breast cancer. |
| Trastuzumab Deruxtecan | AstraZeneca / Daiichi Sankyo | Phase 3 | HER2 | DXd topoisomerase I | HER2+ mBC | Oral | 1021 | Reinforces standard-of-care dominance in HER2+ metastatic breast cancer. |
| Sacituzumab Govitecan | Gilead Sciences | Phase 3 | TROP2 | SN-38 | mTNBC | Oral | LBA1000 | Late-breaker defending the TROP2 lead with long-term durability data. |
| Sacituzumab Tirumotecan (Sac-TMT) | Kelun-Biotech | Phase 3 | TROP2 | Topoisomerase | NSCLC | Oral | 8506 | Challenges TROP2 dominance in NSCLC and underscores the China-origin ADC threat. |
| PDL1V (PF-08046054) | Pfizer | Phase 1 | PD-L1 | Vedotin ADC platform | NSCLC | Poster | 8609 | Early read on a PD-L1-directed ADC + IO combination concept in lung cancer. |
| TUB-040 | Tubulis | Phase 1/2 | NaPi2b | Exatecan (Topo-I) | PROC | Oral | 5513 | A differentiated NaPi2b topo-I ADC showing promise in hard-to-treat ovarian cancer. |
| Disitamab Vedotin (RC48) | Pfizer | Phase 2 | HER2 | MMAE vedotin platform | HR-neg, HER2-low BC | Poster | 598 | Extends vedotin reach into specific HER2-low breast cancer subsets. |
| Sigvotatug Vedotin | Pfizer | Phase 1 | Integrin β6 | MMAE vedotin platform | Solid tumors | Poster | 8522 | Proof-of-concept for a novel target via a validated vedotin platform. |
| BNT326 | BioNTech | Phase 1b/2 | HER3 | Topoisomerase payloads | Solid tumors | Poster | TPS3160 | Evaluates HER3 targeting with a differentiated topo-I payload system. |
| SKB500 | Kelun-Biotech | Phase 1 | Undisclosed | OptiDC™ Platform | Solid tumors | Oral | 3011 | Showcases next-generation platform capability ahead of target disclosure. |
| Disitamab Vedotin (RC48) | Pfizer | Phase 3 | HER2 | MMAE vedotin platform | Gastric Cancer | Poster | TPS4245 | Targeting registration in late-stage gastric cancer via the MMAE platform. |
| Disitamab Vedotin (RC48) | Pfizer | Phase 2/3 | HER2 | MMAE vedotin platform | Gastric Cancer | Poster | LBA4026 | Late-breaker delivering mature gastric cancer data validating RC48 efficacy. |
| BNT324 | BioNTech | Phase 3 | B7H3 | Topoisomerase payloads | mCRPC | Poster | TPS5137 | Pivotal trial design for a B7H3 topo-I ADC in advanced prostate cancer. |
| BNT323 | BioNTech | Phase 3 | HER2 | Topoisomerase payloads | Gynecologic Cancer | Poster | TPS5645 | Expanding HER2 topo-I ADC reach into diverse gynecologic malignancies. |
| Telisotuzumab Vedotin | AbbVie | Phase 2 | c-Met | MMAE vedotin platform | NSCLC | Poster | 8524 | Tests c-Met targeting and combination potential with vedotin technology in lung cancer. |
Strategic Themes to Carry Out of Chicago
ADC + IO combinations move into Phase 3 validation territory.
Bispecific ADCs emerge as the credible next-generation architecture.
Platform chemistry becomes a competitive differentiator on its own.
Payload innovation expands beyond Topo-I and MMAE ecosystems.
Validated targets stretch into broader solid-tumor indications.
The Bottom Line
Vedotin and DXd payload platforms continue to dominate clinical visibility. China-originated ADC innovation is gaining global prominence at speed. And platform differentiation is becoming more strategically important than single-asset positioning.
For oncology strategy, business development and clinical development teams, ASCO 2026 will not just produce data points — it will redraw the boundaries of the ADC competitive map.